研究单位：[1]CHESS Center,Institute of Portal Hypertension,Hepatopancreatobiliary Surgery Institute of Gansu Province[2]Hepatopancreatobiliary Surgery Institute of Gansu Province[3]LanZhou University[4]Huashan Hospital[5]The Sixth People's Hospital of Shenyang City[6]Xingtai City People's Hospital[7]Jinchang Central Hospital[8]Baoding People's Hospital[9]The Third People's Hospital of Zhenjiang City[10]Shanxi Bethune hospital,Shanxi,China[11]Wuhan Jinyintan Hospital[12]Jincheng People's Hospital[13]The Third People's Hospital of Tibet Autonomous Region[14]People's Hospital of Ningxia Hui Autonomous Region[15]Fuling Central Hospital of Chongqing City[16]Hospital of the Chengdu Office of the People's Government of Tibet Autonomous Region[17]The Central Hospital of Lishui City[18]The Third People's Hospital of Linfen City[19]Yibin First People's Hospital[20]Jingzhou Central Hospital[21]Wuxi Fifth People's Hospital[22]Qingyang People's Hospital[23]The First Affiliated Hospital of Anhui Medical University[24]Beilun Hospital of Traditional Chinese Medicine[25]Henan Provincial People's Hospital[26]Qingdao Sixth People's Hospital[27]The First Affiliated Hospital of Xiamen University[28]Shandong Provincial Hospital[29]Beijing YouAn Hospital[30]The First People's Hospital of Taicang[31]Taiyuan Third People's Hospital[32]Tianjin Second People's Hospital[33]Tianjin Third Central Hospital[34]Qishan Hospital of Yantai City[35]Affiliated Hospital of Yunnan University[36]The First People's Hospital of Yunnan[37]The Fourth Affiliated Hospital of Zhejiang University[38]Third Affiliated Hospital,Sun Yat-Sen University[39]First Affiliated Hospital of Chongqing Medical University
研究目的：
COVID-19 pandemic with SARS-CoV-2 infection has become a global challenge. Though most cases of COVID-19 are mild, the disease can also be fatal. Patients with liver disease are more susceptible to damage from SARS-CoV-2 infection considering their immunocompromised status. Therefore, early inoculation of SARS-CoV-2 vaccine in patients with liver disease is an important protective measure. However, information on the effectiveness and safety of the COVID-19 vaccine for liver disease remains to be determined. This muilticentre study (CHESS2101) aims to study the effectiveness and safety of the COVID-19 vaccination for patients with liver disease
